Economic evaluation of cancer drugs: using clinical trial and real-world data
Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few tr...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Boca Raton
CRC Press
[2020]
|
| Schriftenreihe: | Chapman & Hall/CRC biostatistics series
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission |
| Beschreibung: | OCLC-licensed vendor bibliographic record |
| Beschreibung: | 1 online resource |
| ISBN: | 9780429155826 0429155824 9780429546549 0429546548 9781498761314 1498761313 9780429531842 0429531842 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046620610 | ||
| 003 | DE-604 | ||
| 005 | 20220322 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 200310s2020 |||| o||u| ||||||eng d | ||
| 020 | |a 9780429155826 |9 978-0-429-15582-6 | ||
| 020 | |a 0429155824 |9 0-429-15582-4 | ||
| 020 | |a 9780429546549 |9 978-0-429-54654-9 | ||
| 020 | |a 0429546548 |9 0-429-54654-8 | ||
| 020 | |a 9781498761314 |9 978-1-4987-6131-4 | ||
| 020 | |a 1498761313 |9 1-4987-6131-3 | ||
| 020 | |a 9780429531842 |9 978-0-429-53184-2 | ||
| 020 | |a 0429531842 |9 0-429-53184-2 | ||
| 035 | |a (ZDB-7-TFC)9780429155826 | ||
| 035 | |a (DE-599)BVBBV046620610 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 616.99406 |2 23 | |
| 100 | 1 | |a Khan, Iftekhar |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Economic evaluation of cancer drugs |b using clinical trial and real-world data |c Iftekhar Khan, Ralph Crott, and Zahid Bashir |
| 264 | 1 | |a Boca Raton |b CRC Press |c [2020] | |
| 264 | 4 | |c © 2020 | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Chapman & Hall/CRC biostatistics series | |
| 500 | |a OCLC-licensed vendor bibliographic record | ||
| 520 | |a Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. | ||
| 520 | |a The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. | ||
| 520 | |a Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission | ||
| 650 | 7 | |a HEALTH & FITNESS / Diseases / General |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Clinical Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Diseases |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Evidence-Based Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Internal Medicine |2 bisacsh | |
| 650 | 7 | |a MATHEMATICS / Probability & Statistics / General |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Epidemiology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 4 | |a Cancer / Treatment / Economic aspects | |
| 650 | 4 | |a Pharmaceutical industry | |
| 700 | 1 | |a Crott, Ralph |4 aut | |
| 700 | 1 | |a Bashir, Zahid |4 aut | |
| 856 | 4 | 0 | |u https://www.taylorfrancis.com/books/9780429155826 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-7-TFC | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032032342 | ||
Datensatz im Suchindex
| _version_ | 1804181299442745344 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Khan, Iftekhar Crott, Ralph Bashir, Zahid |
| author_facet | Khan, Iftekhar Crott, Ralph Bashir, Zahid |
| author_role | aut aut aut |
| author_sort | Khan, Iftekhar |
| author_variant | i k ik r c rc z b zb |
| building | Verbundindex |
| bvnumber | BV046620610 |
| collection | ZDB-7-TFC |
| ctrlnum | (ZDB-7-TFC)9780429155826 (DE-599)BVBBV046620610 |
| dewey-full | 616.99406 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99406 |
| dewey-search | 616.99406 |
| dewey-sort | 3616.99406 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04528nmm a2200577zc 4500</leader><controlfield tag="001">BV046620610</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20220322 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">200310s2020 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780429155826</subfield><subfield code="9">978-0-429-15582-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0429155824</subfield><subfield code="9">0-429-15582-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780429546549</subfield><subfield code="9">978-0-429-54654-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0429546548</subfield><subfield code="9">0-429-54654-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781498761314</subfield><subfield code="9">978-1-4987-6131-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1498761313</subfield><subfield code="9">1-4987-6131-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780429531842</subfield><subfield code="9">978-0-429-53184-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0429531842</subfield><subfield code="9">0-429-53184-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-7-TFC)9780429155826</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046620610</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99406</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Khan, Iftekhar</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Economic evaluation of cancer drugs</subfield><subfield code="b">using clinical trial and real-world data</subfield><subfield code="c">Iftekhar Khan, Ralph Crott, and Zahid Bashir</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boca Raton</subfield><subfield code="b">CRC Press</subfield><subfield code="c">[2020]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Chapman & Hall/CRC biostatistics series</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">OCLC-licensed vendor bibliographic record</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. </subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. </subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Clinical Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Diseases</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Evidence-Based Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Internal Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MATHEMATICS / Probability & Statistics / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Epidemiology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer / Treatment / Economic aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crott, Ralph</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bashir, Zahid</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.taylorfrancis.com/books/9780429155826</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-7-TFC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032032342</subfield></datafield></record></collection> |
| id | DE-604.BV046620610 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T14:08:06Z |
| indexdate | 2024-07-10T08:49:27Z |
| institution | BVB |
| isbn | 9780429155826 0429155824 9780429546549 0429546548 9781498761314 1498761313 9780429531842 0429531842 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032032342 |
| open_access_boolean | |
| physical | 1 online resource |
| psigel | ZDB-7-TFC |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | CRC Press |
| record_format | marc |
| series2 | Chapman & Hall/CRC biostatistics series |
| spelling | Khan, Iftekhar Verfasser aut Economic evaluation of cancer drugs using clinical trial and real-world data Iftekhar Khan, Ralph Crott, and Zahid Bashir Boca Raton CRC Press [2020] © 2020 1 online resource txt rdacontent c rdamedia cr rdacarrier Chapman & Hall/CRC biostatistics series OCLC-licensed vendor bibliographic record Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh MATHEMATICS / Probability & Statistics / General bisacsh MEDICAL / Epidemiology bisacsh MEDICAL / Pharmacology bisacsh Cancer / Treatment / Economic aspects Pharmaceutical industry Crott, Ralph aut Bashir, Zahid aut https://www.taylorfrancis.com/books/9780429155826 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Khan, Iftekhar Crott, Ralph Bashir, Zahid Economic evaluation of cancer drugs using clinical trial and real-world data HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh MATHEMATICS / Probability & Statistics / General bisacsh MEDICAL / Epidemiology bisacsh MEDICAL / Pharmacology bisacsh Cancer / Treatment / Economic aspects Pharmaceutical industry |
| title | Economic evaluation of cancer drugs using clinical trial and real-world data |
| title_auth | Economic evaluation of cancer drugs using clinical trial and real-world data |
| title_exact_search | Economic evaluation of cancer drugs using clinical trial and real-world data |
| title_exact_search_txtP | Economic evaluation of cancer drugs using clinical trial and real-world data |
| title_full | Economic evaluation of cancer drugs using clinical trial and real-world data Iftekhar Khan, Ralph Crott, and Zahid Bashir |
| title_fullStr | Economic evaluation of cancer drugs using clinical trial and real-world data Iftekhar Khan, Ralph Crott, and Zahid Bashir |
| title_full_unstemmed | Economic evaluation of cancer drugs using clinical trial and real-world data Iftekhar Khan, Ralph Crott, and Zahid Bashir |
| title_short | Economic evaluation of cancer drugs |
| title_sort | economic evaluation of cancer drugs using clinical trial and real world data |
| title_sub | using clinical trial and real-world data |
| topic | HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh MATHEMATICS / Probability & Statistics / General bisacsh MEDICAL / Epidemiology bisacsh MEDICAL / Pharmacology bisacsh Cancer / Treatment / Economic aspects Pharmaceutical industry |
| topic_facet | HEALTH & FITNESS / Diseases / General MEDICAL / Clinical Medicine MEDICAL / Diseases MEDICAL / Evidence-Based Medicine MEDICAL / Internal Medicine MATHEMATICS / Probability & Statistics / General MEDICAL / Epidemiology MEDICAL / Pharmacology Cancer / Treatment / Economic aspects Pharmaceutical industry |
| url | https://www.taylorfrancis.com/books/9780429155826 |
| work_keys_str_mv | AT khaniftekhar economicevaluationofcancerdrugsusingclinicaltrialandrealworlddata AT crottralph economicevaluationofcancerdrugsusingclinicaltrialandrealworlddata AT bashirzahid economicevaluationofcancerdrugsusingclinicaltrialandrealworlddata |